Hepatocyte growth factor gene-introduced AAV vector optimized for intrathecal administration

By combining AAV vectors with specific promoters and polyadenylation sequences, the problem of low productivity and expression levels of AAV vectors when administered intrathecally, achieving efficient expression of hepatocyte growth factor proteins for the treatment of muscular atrophy lateral sclerosis and diabetic peripheral neuropathy.

CN119095971APending Publication Date: 2024-12-06HELIXMITH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202380036395.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-27
Filing Date
2023-04-21
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing adeno-associated virus (AAV) vectors are low in productivity and have low protein expression levels when administered intrathecally, making it difficult to effectively treat genetic and difficult diseases.

Method used

By combining specific promoters, AAV serotypes and polyadenylation sequences, a new AAV vector was developed, including the CMV promoter or EF-1alpha promoter and the polynucleic acid sequence encoding hepatocyte growth factor, improving the production of AAV particles and protein expression levels.

Benefits of technology

The productivity of AAV particles and the protein expression during intrathecal administration are significantly improved, providing an effective pharmaceutical composition for the prevention or treatment of amyotrophic lateral sclerosis and diabetic peripheral neuropathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095971A_ABST
    Figure CN119095971A_ABST
Patent Text Reader

Abstract

The present invention relates to an adeno-associated virus (AAV) vector into which a hepatocyte growth factor gene is introduced, which is optimized for intrathecal administration. The AAV vector and the AAV particle prepared by the same according to the present invention have excellent productivity of the AAV particle comprising the hepatocyte growth factor gene, and also have very excellent expression efficiency of hepatocyte growth factor when administered into the sheath of a mammal. Therefore, when the AAV vector and the particle of the present invention are used in intrathecal administration, the AAV vector and the particle can be effectively used in the prevention or treatment of related diseases by inducing the expression of a hepatocyte growth factor protein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the priority of Korean Patent Application No. 10-2022-0052369 filed on April 27, 2022, in the Korean Intellectual Property Office, the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to an adeno-associated virus (AAV) vector for introducing a hepatocyte growth factor gene optimized for intrathecal administration. [Background technology]

[0003] Gene therapy is a method of treating genetic diseases and intractable diseases by delivering therapeutic genes into the patient's cells using gene recombination technology to cause genetic deformation or expression of specific proteins in the target cells. In this case, the substance that delivers the gene into the body is called a transporter or vector. Vectors are generally divided into viral vectors and non-viral vectors. Representative viral vectors include retroviruses and adenoviruses, and non-viral vectors include naked DNA and liposomes.

[0004] In order to utilize gene therapy of hepatocyte growth factor, the inventors have prepared adeno-associated virus into which the hepatocyte growth factor gene is introduced (Lee et al., BBRC 517: 452-457, 2019; Lee et al., Acta Neuropathologica Communications 7: 14, 2019). However, the existing AAV has the limitations of low productivity and very low protein expression level during intrathecal administration. Therefore, it is necessary to develop a new AAV vector with improved productivity and optimized for intrathecal administration to increase the expression level of the protein.

[0005] Many papers and patent documents are referenced throughout this specification and their citations are marked. The disclosures of the cited papers and patent documents are incorporated into this specification as references to more clearly illustrate the level of the technical field to which the present invention belongs and the content of the present invention. [Summary of the invention]

[0006]

Technical issues

[0007] The present inventors have made many efforts to develop a novel AAV (adeno-associated virus) vector with improved productivity and protein expression level. Finally, the present inventors confirmed that the productivity of AAV particles is greatly improved when a specific promoter, AAV serotype, and polyadenylation sequence are combined. In addition, the present inventors found that the expression of the protein is greatly improved when the above-mentioned AAV particles are administered intrathecally, thereby completing the present invention.

[0008] Therefore, an object of the present invention is to provide an AAV vector for introducing a hepatocyte growth factor gene optimized for intrathecal administration, an AAV particle, and a pharmaceutical composition comprising the same.

[0009] Other objects and advantages of the present invention will be further clarified through the following detailed description of the present invention, the scope of protection of the invention and the accompanying drawings.

[0010]

Technical solution

[0011] According to one embodiment of the present invention, the present invention provides an AAV vector comprising a nucleic acid molecule, wherein the nucleic acid molecule comprises:

[0012] (a) CMV promoter sequence or EF-1alpha promoter sequence; and

[0013] (b) a polynucleic acid sequence encoding hepatocyte growth factor operably linked to the above promoter sequence.

[0014] The present inventors have made many efforts to develop a novel AAV vector with improved productivity and protein expression level. Finally, the present inventors confirmed that the productivity of AAV particles is greatly improved when a specific promoter, AAV serotype, and polyadenylation sequence are combined. In addition, the present inventors found that the expression amount of protein is greatly improved when the above-mentioned AAV particles are administered intrathecally.

[0015] In this specification, the term "vector" refers to a non-chromosomal nucleic acid including a complete replicon that can be replicated when it is configured in a cell through a transformation process. The above-mentioned vector can be viral or non-viral. Viral vectors include retroviruses, adenoviruses, adeno-associated viruses (AAV), herpesviruses, baculoviruses, deformed baculoviruses, papoviruses, etc., but are not limited to them. Non-viral vectors for delivering nucleic acids include: naked DNA; DNA formed into a complex with cationic lipids composed of a single or combined cationic polymer; anionic and cationic liposomes; DNA-protein complexes and particles containing DNA condensed with cationic polymers such as heterologous polylysine, oligopeptides of a specified length, and polyethyleneimine contained in the liposomes in some cases; and ternary complexes containing viruses and polylysine-DNA.

[0016] "Viral vector" is defined as a virus or virus particle generated by recombination that contains a polynucleotide that is delivered to a host cell in any case in vivo, in vitro or in the laboratory. Examples of viral vectors include retroviral vectors, AAV vectors, lentiviral vectors, adenoviral vectors, alphaviral vectors, etc. Alphaviral vectors, for example, vectors based on Semliki Forest virus and vectors based on Sindbis virus are also developed for use in gene therapy and immunotherapy (see Schlesinger and Dubensky (1999) Curr. Opin. Biotechnol. 5: 434-439 and Ying, et al. (1999) Nat. Med. 5 (7): 823-827).

[0017] The above-mentioned vector may contain a nucleic acid sequence that is replicable in a host cell, such as a replication origin. The vector may lack a nucleic acid sequence that is replicable in a host cell. In addition, the vector may contain a target gene, one or more selectable marker genes, and other gene elements known in the technical field to which the present invention belongs, or any other appropriate insert.

[0018] In one embodiment of the present invention, "adeno-associated virus" or "AAV" belongs to the genus dependoparvovirus of the family parvoviridae. Various serotypes of the virus are known to be suitable for delivery of nucleic acids. At least 11 numbered serotypes of AAV are known in the art to which the present invention belongs: AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, AAV9, AAV10, AAV11, AAV12 and AAV13.

[0019] In one embodiment of the present invention, the above-mentioned AAV serotypes include the following variant serotypes: AAV-DJ.AAV-DJ / 8, AAV-PHP.Eb, AAV-PHP.S and AAV rh10.

[0020] In this specification, the term "AAV vector" refers to a vector containing inverted terminal repeat sequences (ITR sequences) on both sides (through ITR sequence plating) and containing one or more target polynucleotides (or introduced genes). AAV vectors are vectors that encode and express viral DNA replication (rep) and encapsidation (cap) gene products, and when present in transfected host cells, they can be replicated and packaged into infectious virus particles.

[0021] "AAV virion," "AAV viral particle," or "AAV vector particle" means a viral particle composed of at least one AAV capsid protein or an encapsidated polynucleotide AAV vector.

[0022] The above-mentioned "AAV" is a replication-deficient parvovirus, and its single-stranded DNA genome is about 4.7 kb in length and contains two nucleotide inverted terminal repeat sequences (ITR sequences). AAV has multiple serotypes. The nucleotide sequences of the above-mentioned AAV serotype genomes are well known in the technical field to which the present invention belongs. For example, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-2 is provided in GenBank Accession No. NC_001401 and in Srivastava et al., J. Virol., 45:555-564 (1983); the complete genome of AAV-3 is provided by GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided by GenBank Accession No. NC_001829; the AAV-5 genome is provided by GenBank Accession No. AF085716; the complete genome of AAV-6 is provided by GenBank Accession No. NC_00 1862; at least a portion of the AAV-7 and AAV-8 genomes are provided by GenBank Accession Nos. AX753246 and AX753249, respectively; the AAV-9 genome is provided in Gao et al., J. Virol., 45:555-564 (1983). al., J. Virol., 78:6381-6388 (2004); the AAV-10 genome is provided in Mol. Ther., 13(1):67-76 (2006); and the AAV-11 genome is provided in Virology, 330(2):375-383 (2004).

[0023] In one example of the present invention, the genome of the above-mentioned AAV can be a self-complementary genome. In this case, the AAV ITR sequence contains cis (Cis) action sequences that indicate DNA replication (rep), encapsidation (cap) / packaging and host cell chromosome integration. The Rep protein has a variety of enzyme properties that ultimately play a role in the replication of the viral genome. The Cap gene is expressed from the p40 promoter and encodes three capsid proteins VP1, VP2 and VP3. On the other hand, in order to generate AAV vectors, rep protein and cap protein can be provided in trans.

[0024] AAV can be packaged using viral packaging systems such as retrovirus, adenovirus, herpes virus, or baculovirus packaging systems.

[0025] In one embodiment of the present invention, packaging can be achieved by using a helper virus or a helper plasmid and a cell line. The helper virus or the helper plasmid contains elements and sequences (E4, E2a, VA, etc.) that facilitate the transfer of genetic materials into cells.

[0026] For example, a helper plasmid may comprise at least one helper DNA sequence derived from a replication-incompetent viral genome that trans-encodes all virion proteins required for packaging of replication-incompetent AAV and for generating virion proteins that can contain the replication-incompetent AAV at high titers without generating replication-incompetent AAV.

[0027] During the packaging process, in order to generate a supernatant containing high-titer recombinant virus, the helper plasmid and plasmid encoding AAV viral proteins are temporarily co-transfected into mammalian cells such as human embryonic kidney cells that can produce virus, for example, 293 cells (ATCC No. CRL1573, ATCC, Rockville, Md.).

[0028] In this specification, the term "promoter" refers to a coding sequence, for example, any sequence that regulates gene expression. Promoters can be, for example, structural, inducible, consistent or tissue-specific. A "promoter" is a region of a polynucleotide sequence that controls the start and rate of transcription.

[0029] In one embodiment of the present invention, the above-mentioned promoter includes Rous sarcoma virus (RSV) LTR promoter (optionally including RSV enhancer), cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, phosphoglycerol kinase (PGK) promoter, U6 promoter or EF-1alpha (Elongation Factor 1α) promoter, but is not limited thereto.

[0030] In a specific example of the present invention, the above promoter is CMV promoter or EF-1alpha promoter.

[0031] In this specification, the term "nucleic acid molecule" has the meaning of including DNA (gDNA and cDNA) and RNA molecules. The nucleotides as the basic structural units in nucleic acid molecules include not only natural nucleotides but also analogues with deformed sugar or base sites (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90: 543-584 (1990)).

[0032] It should be clear to those skilled in the art that the nucleotide sequence encoding the hepatocyte growth factor of the present invention is not limited to a specific nucleotide sequence as long as it encodes the amino acid sequence constituting the hepatocyte growth factor or its isomers.

[0033] This is because, even if the nucleotide sequence mutates, when the mutated nucleotide sequence is expressed as a protein, there are cases where the protein sequence is not changed. This is called the degeneracy of the codon. Therefore, the above-mentioned nucleotide sequence includes nucleotide sequences containing codons that are functionally equivalent, codons that encode the same amino acid (for example, due to the degeneracy of the codon, there are six codons for arginine and serine) or codons that encode biologically equivalent amino acids.

[0034] When considering the above-mentioned variants with biologically equivalent activities, the above-mentioned nucleic acid molecule of the present invention encoding the amino acid sequence constituting the hepatocyte growth factor should also be interpreted as including sequences that show substantial identity therewith. The above-mentioned substantial identity means that after aligning the above-mentioned sequence of the present invention with any other sequence in a maximum correspondence manner, when analyzing the aligned sequences using a common algorithm in the technical field to which the present invention belongs, at least 60% homology (for example, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68% or 69%) is shown, and more specifically, 70% homology (for example, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78% or 79%) is shown. 7%, 78% or 79%), more specifically, showing more than 80% homology (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% or 89%), more specifically, showing more than 90% homology (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%), and most specifically, showing more than 95% homology (e.g., 95%, 96%, 97%, 98% or 99%). All integers above 60% and below 100% and decimals therein are included within the scope of the present invention in relation to the percentage (%) homology.

[0035] Alignment methods for sequence comparison are well known in the art to which the present invention belongs. Various methods and algorithms for alignment are described in Smith and Waterman, Adv. Appl. Math. 2:482 (1981); Needleman and Wunsch, J. Mol. Bio. 48:443 (1970); Pearson and Lipman, Methods in Mol. Biol. 24:307-31 (1988); Higgins and Sharp, Gene 73:237-44 (1988); Higgins and Sharp, CABIOS 5:151-3 (1989); Corpet et al., Nuc. Acids Res. 16:10881-90 (1988); Huang et al., Comp. Appl. BioSci. 8:155-65 (1992) and Pearson et al., Methods in MoI ... al., Meth. Mol. Biol. 24: 307-31 (1994). NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215: 403-10 (1990)) can be accessed in NCBI (National Center for Biological Information) and the like, and can be used in conjunction with sequence analysis software such as blastp, blastn, blastx, tblastn and tblastx on the Internet. BLAST can be connected through the BLAST homepage of the ncbi website. The homology comparison method using this program can be confirmed in the BLAST help homepage of the ncbi website.

[0036] In one example of the present invention, the AAV vector of the present invention may contain a polynucleotide sequence encoding any polypeptide having other functions to replace the polynucleotide sequence encoding the hepatocyte growth factor.

[0037] In this specification, the term "operatively linked" refers to the functional combination between a nucleic acid expression regulatory sequence (e.g., a promoter, a signal sequence or an array of transcriptional regulatory factor binding sites) and other nucleic acid sequences, through which the regulatory sequence regulates the transcription and / or interpretation of the other nucleic acid sequences.

[0038] In one embodiment of the present invention, the above-mentioned hepatocyte growth factor is a hepatocyte growth factor isoform (HGF isoform). The term "isoform of HGF" used in the present specification refers to an HGF polypeptide having at least 80%, for example, 80%, 85%, 90%, 95% homology with the amino acid sequence of HGF naturally occurring in animals, including all variants including all opposing genes. For example, HGF isoform has the meaning including all normal forms or wild types of HGF and various variants of HGF (for example, splice variants and deletion variants).

[0039] In one embodiment of the present invention, the HGF isoform is full-length HGF (flHGF), deleted variant HGF (dHGF) or a combination thereof, but is not limited thereto.

[0040] In the present specification, the term "flHGF" refers to the amino acid sequence 1-728 of the amino acid sequence of animal HGF, according to one example, it refers to the amino acid sequence 1-728 of the amino acid sequence of mammalian HGF, and according to another example, it refers to the amino acid sequence 1-728 of the amino acid sequence of human HGF.

[0041] In the present specification, the term "dHGF" refers to a deletion variant of HGF protein generated by alternative splicing of an animal HGF gene, and according to one example, refers to a deletion variant of HGF protein generated by alternative splicing of a mammalian HGF gene. According to another example of the present invention, the dHGF of the present invention refers to HGF consisting of 723 amino acids in which 5 amino acids (F, L, P, S, and S) are deleted in the first Klingel domain of the α chain of the full-length HGF sequence.

[0042] In one embodiment of the present invention, HGF isoforms can be encoded by expressing two or more different types of isoforms, for example, by a hybrid HGF gene expressing flHGF and dHGF simultaneously.

[0043] In one embodiment of the present invention, the hybrid HGF gene comprises: a sequence corresponding to exons 1 to 4 of the human HGF gene; an intron 4 of the human HGF gene or a fragment thereof; and a sequence corresponding to exons 5 to 18 of the human HGF gene.

[0044] In a specific example of the present invention, the full-length hepatocyte growth factor comprises the amino acid sequence of sequence 1, and the deleted variant hepatocyte growth factor comprises the amino acid sequence of sequence 2, but is not limited thereto.

[0045] In one example of the present invention, the hybrid HGF gene comprising intron 4 is 7113 bp in length and comprises the nucleotide sequence of sequence 3.

[0046] In another embodiment of the present invention, the hybrid HGF gene may selectively include a fragment of intron 4 between exon 4 and exon 5 of HGF cDNA.

[0047] In one example of the present invention, the polynucleotide sequence of the gene inserted into the AAV vector of the present invention can be deformed for the stable expression of the polypeptide encoded by the polynucleotide sequence. The above deformation can be to replace the entire intron sequence of the inserted gene by deforming only a part of the intron sequence, thereby shortening the length of the inserted polynucleotide sequence.

[0048] In a more specific example of the present invention, the hybrid HGF gene comprises a nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID NOs. 5 to 9 and SEQ ID NOs. 19. The nucleotide sequences of SEQ ID NOs. 5 to 8 represent HGF-X7-d1 to HGF-X7-d4 genes whose nucleotide sequence lengths are shortened by including only a portion of the intron 4 sequence of the HGF gene in the nucleotide sequence of HGF-X7 represented by SEQ ID NOs. 4.

[0049] The contents of the "HGF isoforms" and "hybrid HGF genes" (eg, HGF-X7) of the present invention are reported in WO 2003 / 078568, and the disclosure of the above patent document is incorporated herein by reference in its entirety.

[0050] In one embodiment of the present invention, the polynucleotide sequence encoding hepatocyte growth factor or its isoforms is codon-optimized.

[0051] In a specific example of the present invention, the codon-optimized polynucleotide sequence encoding hepatocyte growth factor or its isologous isomers comprises the nucleotide sequence of sequence 9.

[0052] In one example of the present invention, the polynucleotide sequence encoding the hepatocyte growth factor or its isologues may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology with a nucleotide sequence selected from the group consisting of the nucleotide sequences of sequence 4 to sequence 9 or sequence 19, but is not limited thereto.

[0053] In one example of the present invention, the AAV vector is an AAV vector of serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, AAV-DJ / 8, AAV-PHP.Eb, AAV-PHP.S or AAVrh10, but is not limited thereto.

[0054] In one example of the present invention, the vector is an AAV vector of serotype AAV1 or AAV9.

[0055] In one example of the present invention, the above-mentioned CMV promoter sequence may include the nucleotide sequence of sequence 10 or 11, or may include a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology with the nucleotide sequence of the above-mentioned sequence 10 or sequence 11.

[0056] In one embodiment of the present invention, the CMV promoter sequence may include a fragment of the entire CMV promoter sequence. The fragment includes the functional minimum sequence of the CMV promoter sequence. For example, the CMV promoter sequence may include the nucleotide sequence of sequence 10, and may also include the CMV promoter sequence at the 5'-terminal part or the 3'-terminal part based on the fragment.

[0057] In one example of the present invention, the EF-1alpha promoter sequence may include the nucleotide sequence of SEQ ID NO: 12, or may include a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the nucleotide sequence of SEQ ID NO: 12. All integers and decimals between 90% and 100% are related to the percentage (%) homology and are included in the scope of the present invention.

[0058] In one embodiment of the present invention, the nucleic acid molecule further comprises a posttranscriptional regulatory element (PRE).

[0059] In a specific example of the present invention, the post-transcriptional regulatory element includes a Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), but is not limited thereto.

[0060] In one embodiment of the present invention, the nucleic acid molecule further comprises a polyadenylation sequence.

[0061] In one embodiment of the present invention, the polyadenylation sequence includes a human growth hormone (hGH) polyadenylation sequence, a bovine growth hormone (bGH) polyadenylation sequence, a SV40 polyadenylation sequence or a combination thereof, but is not limited thereto.

[0062] In a specific example of the present invention, the human growth hormone polyadenylation sequence may include the nucleotide sequence of SEQ ID NO: 13 or SEQ ID NO: 14, or may include a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the nucleotide sequence of SEQ ID NO: 13 or SEQ ID NO: 14. All integers and decimals between 90% and 100% are included in the scope of the present invention in relation to the percentage (%) homology.

[0063] In one embodiment of the present invention, the human growth hormone polyadenylation sequence may include a fragment of the entire hGH sequence. The fragment includes the functional minimum sequence of the hGH polyadenylation sequence. For example, the hGH polyadenylation sequence may include the nucleotide sequence of sequence 13, and may also include the hGH polyadenylation sequence at the 5′-terminal portion or the 3′-terminal portion based on the fragment.

[0064] In a specific example of the present invention, the bovine growth hormone polyadenylation sequence may include the nucleotide sequence of SEQ ID NO: 15 or SEQ ID NO: 16, or may include a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the nucleotide sequence of SEQ ID NO: 15 or SEQ ID NO: 16. All integers above 90% and below 100% and decimals therein are related to the percentage (%) homology and are included in the scope of the present invention.

[0065] In one embodiment of the present invention, the polyadenylation sequence of bovine growth hormone (bGH) may include a fragment of the entire polyadenylation sequence of bGH. The fragment includes the functional minimum sequence of the polyadenylation sequence of bGH. For example, the polyadenylation sequence of bGH may include the nucleotide sequence of sequence 15, and may also include the polyadenylation sequence of bGH at the 5'-terminal part or the 3'-terminal part based on the fragment.

[0066] In a specific example of the present invention, the SV40 polyadenylation sequence may include the nucleotide sequence of SEQ ID NO: 17 or SEQ ID NO: 18, or may include a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the nucleotide sequence of SEQ ID NO: 17 or SEQ ID NO: 18. All integers above 90% and below 100% and decimals therein are related to the percentage (%) homology and are included within the scope of the present invention.

[0067] In one embodiment of the present invention, the SV40 polyadenylation sequence may include a fragment of the entire SV40 polyadenylation sequence. The fragment includes the functional minimum sequence of the SV40 polyadenylation sequence. For example, the SV40 polyadenylation sequence may include the nucleotide sequence of sequence 17, and may also include the SV40 polyadenylation sequence at the 5′-terminal portion or the 3′-terminal portion based on the fragment.

[0068] In one embodiment of the present invention, the nucleic acid molecule comprises two AAV inverted terminal repeat sequences on both sides of the nucleic acid sequence.

[0069] According to yet another embodiment of the present invention, the present invention provides an isolated host cell comprising the above-mentioned AAV vector.

[0070] The host cells that can stably and continuously clone and express the AAV vector of the present invention can use any host cells known in the technical field to which the present invention belongs. For example, eukaryotic host cells suitable for the above-mentioned vectors include Saccharomyce cerevisiae, insect cells, monkey kidney cells 7 (COS7: monkey kidney cells), NSO cells SP2 / 0, Chinese hamster ovary (CHO: Chinese hamster ovary) cells, W138, baby hamster kidney (BHK: babyhamster kidney) cells, MDCK, myeloma cell lines, HuT 78 cells and HEK-293 cells, but are not limited thereto.

[0071] The term "transformation", "transduction" or "transfection" in this specification refers to the process of transferring or introducing exogenous nucleic acid into a host cell. "Transformed", "transduced" or "transfected" cells are cells transformed, transduced or transfected by exogenous nucleic acid, including the cells and the progeny cells subcultured therefrom.

[0072] When the host cell is a eukaryotic cell, the vector of the present invention can be delivered into the host cell by microinjection (Capecchi, MR, Cell, 22: 479 (1980)), calcium phosphate precipitation (Graham, FL et al., Virology, 52: 456 (1973)), electroporation (Neumann, E. et al., EMBO J., 1: 841 (1982)), liposome-mediated transfection (Wong, TK et al., Gene, 10: 87 (1980)), DEAE-dextran treatment (Gopal, Mol. Cell Biol., 5: 1188-1190 (1985)) and gene gun method (Yang et al., Proc. Natl. Acad. Sci., 87: 9568-9572 (1990)).

[0073] In the present invention, the vector injected into the host cell can express the protein required for preparing AAV virus particles in the host cell, and the AAV virus particles can be obtained through the action of the expressed proteins and their assembly.

[0074] The above-mentioned culture is usually carried out under aerobic conditions such as shaking culture or rotation of a rotator. The culture temperature is preferably in the range of 10°C to 40°C, and the culture time is usually 5 hours to 7 days. The pH of the culture medium is preferably maintained in the range of 3.0 to 9.0 during the culture. The pH of the culture medium can be adjusted by organic or inorganic acids, alkaline solutions, urea, calcium carbonate, ammonia, etc. If necessary, antibiotics such as ampicillin, streptomycin, chloramphenicol, kanamycin and tetracycline can be added during the culture for the maintenance and expression of the recombinant vector. When culturing host cells transformed by a recombinant vector with an inducible promoter, if necessary, an appropriate inducer can be added to the culture medium. For example, in the case where the expression vector contains a lac promoter, isopropyl-β-D-thiogalactopyranoside (IPTG, isopropyl-beta-D-thiogalactopyranoside) can be added, and in the case of containing a trp promoter, indoleacrylic acid can be added to the culture medium.

[0075] According to another embodiment of the present invention, the present invention provides an AAV particle comprising the above-mentioned AAV vector.

[0076] In one embodiment of the present invention, the AAV particles are used for intrathecal administration.

[0077] The AAV particles of one embodiment of the present invention have an excellent effect of expressing the transformed gene of interest (GOI) as a protein when administered intrathecally.

[0078] According to another embodiment of the present invention, the present invention provides a pharmaceutical composition comprising the above-mentioned AAV particles for preventing or treating amyotrophic lateral sclerosis (ALS) or diabetic peripheral neuropathy (DPN).

[0079] In one embodiment of the present invention, the diabetic peripheral neuropathy is polyneuropathy or focal neuropathy.

[0080] The pharmaceutical composition of the present invention utilizes the above-mentioned AAV vector or AAV particle of the present invention as an active ingredient. Therefore, in order to avoid excessive complexity of this specification, the common contents between the two will be omitted.

[0081] The pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate and mineral oil, etc., which are commonly used during preparation, but are not limited thereto. In addition to the above-mentioned ingredients, the pharmaceutical composition of the present invention may also include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. Suitable pharmaceutically acceptable carriers and preparations are recorded in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0082] The pharmaceutical composition of the present invention can be administered orally or parenterally, for example, intravenously, intrathecally, intraspinally, intracerebrally, intraventricularly, intracranially, intramuscularly, intraperitoneally, intrasternally, focally, intranasally, intrapulmonaryly, and intrarectally, etc. Preferably, intrathecal administration is possible, but not limited thereto.

[0083] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, gender, disease state, diet, administration time, administration route, metabolic rate and reaction sensitivity. Generally, a skilled physician can easily determine and prescribe an effective dosage for the desired treatment or prevention.

[0084] According to a preferred embodiment of the present invention, based on AAV virus particles, the daily dosage of the pharmaceutical composition of the present invention is 1×10 9 -1×10 12 The term "pharmaceutically effective amount" in this specification refers to an amount sufficient to prevent or treat the above-mentioned diseases.

[0085] The term "prevention" in this specification refers to a method or protective treatment of a disease or disease state. The term "treatment" in this specification refers to the reduction, inhibition, stabilization or eradication of a disease state.

[0086] The pharmaceutical composition of the present invention can be prepared using pharmaceutically acceptable carriers and / or excipients according to methods that are easily implemented by those skilled in the art to which the present invention belongs, and can be prepared in unit dosage form or in multi-dose containers. In this case, the dosage form can be a solution, suspension or emulsion in an oil or aqueous solvent, or an extract, powder, suppository, powder, granule, tablet or capsule, and may also contain a dispersant or stabilizer.

[0087] According to another embodiment of the present invention, the present invention provides a method for preventing or treating amyotrophic lateral sclerosis or diabetic peripheral neuropathy, comprising the step of administering the above pharmaceutical composition to a subject in need of treatment.

[0088] In one example of the present invention, the pharmaceutical composition comprises the AAV vector, isolated host cells comprising the AAV vector, and AAV particles comprising the AAV vector as active ingredients.

[0089] The above-mentioned object of the present invention is a mammal such as a human, a chimpanzee, an orangutan, a primate other than a human, a dog, a cat, a horse, a hamster, a mouse, a rat, a gerbil, a pig, a sheep, a cow, etc., and most specifically, a human, but it is not limited thereto.

[0090] The method for preventing or treating amyotrophic lateral sclerosis or diabetic peripheral neuropathy of the present invention comprises the step of administering the pharmaceutical composition of one embodiment of the present invention. To avoid excessive complexity of the present specification, the description of repeated contents will be omitted.

[0091] [Effects of the Invention]

[0092] The present invention provides an AAV vector and AAV particles for introducing a hepatocyte growth factor gene optimized for intrathecal administration, and a pharmaceutical composition comprising the same for preventing or treating amyotrophic lateral sclerosis or diabetic peripheral neuropathy.

[0093] The AAV vector and AAV particles of the present invention have excellent productivity of AAV particles containing the hepatocyte growth factor gene, and when they are administered intrathecally to mammals, the expression efficiency of the hepatocyte growth factor is also very excellent. Therefore, when the AAV vector and particles of the present invention are used in intrathecal administration, they can be effectively used in the prevention or treatment of related diseases by inducing the expression of the hepatocyte growth factor protein.

Brief Description of the Drawings

[0094] Figure 1 It is a diagram showing the composition of the AAV vector candidate group shown in Table 1 of the present invention according to the types of promoter, GOI and polyadenylation sequence.

[0095] Figure 2 The graph shows the hHGF expression level according to the composition of the AAV vector candidate group in Table 1 of the present invention for comparison.

[0096] Figure 3 This is a graph showing the comparative productivity of AAV particles prepared according to the compositions of the AAV vector candidate group of Table 1 of the present invention.

[0097] Figure 4 A graph showing the hHGF expression levels after intrathecal administration to mice after AAV particles were prepared according to the composition of the AAV vector candidate group in Table 2 of the present invention. [Specific implementation method]

[0098] The present invention is described in more detail below by way of examples. However, it should be apparent to those skilled in the art that these examples are used to more specifically describe the present invention, and according to the gist of the present invention, the scope of the present method maze is not limited to these examples.

[0099] [Example]

[0100] Throughout this specification, "%" used to express the concentration of a specific substance, unless otherwise specified, means solid / solid is (weight / weight)%, solid / liquid is (weight / volume)%, and liquid / liquid is (volume / volume)%.

[0101] [Example 1: Preparation of candidate plasmids and comparison of expression efficiency (in vitro)]

[0102] The present inventors prepared six types of plasmids containing different promoters and poly A tails by cloning in the following manner.

[0103] (1) A backbone sequence (SEQ ID NO: 20) comprising ITR(L) and ITR(R) was obtained by synthesis.

[0104] (2) CMV promoter (SEQ ID NO: 11) and EF-1alpha S series promoter (SEQ ID NO: 12) were synthesized as promoters to include MluI and ClaI restriction enzyme sequences, respectively, and inserted into the backbone.

[0105] (3) The HGF-X7-d4 sequence of sequence 8 was inserted using the ClaI and SalI restriction enzyme sequences.

[0106] (4) hGH poly A tail (sequence 14), bGH poly A tail (sequence 16) and SV40 poly A tail (sequence 18) as candidate sequences for Poly(A) were synthesized in a manner that included SalI and RsrI restriction enzyme sequences and inserted into the backbone.

[0107] The composition of the 6 plasmids is shown in Table 1 and Figure 1 VM202 (pCK-HGF-X7) was used as a positive control group.

[0108]

Table 1

[0109] Serial number Promoter Expressed gene Poly A tail 1 CMV (1160 bp) HGFX7d4 (2879 bp) hGH pA (542 bp) 2 CMV (1160 bp) HGFX7d4 (2879 bp) bGH pA (317 bp) 3 CMV (1160 bp) HGFX7d4 (2879 bp) SV40 pA (185 bp) 4 EF-1alpha S(784bp) HGFX7d4 (2879 bp) hGH pA (542 bp) 5 EF-1alpha S(784bp) HGFX7d4 (2879 bp) bGH pA (317 bp) 6 EF-1alpha S(784bp) HGFX7d4 (2879 bp) SV40 pA (185 bp)

[0110] Figure 1 It is a schematic diagram showing the composition of the AAV vector candidate group shown in Table 1 of the present invention according to the types of promoter, GOI and polyadenylation sequence.

[0111] HEK293 cells were cultured in DMEM + 10% fetal bovine serum (FBS). One day before transfection, 1×10 5 cells / well were seeded in a 6-well plate. On the second day, 0.5ug of NC (negative control), VM202 (positive control), and plasmids 1 to 6 were added and transfected using PEI. After 72 hours, the supernatant was collected and subjected to human HGF ELISA (R&D, DHG00). The results are shown in Table 1. Figure 2 shown. Figure 2 The graph shows the hHGF expression level according to the composition of the AAV vector candidate group in Table 1 of the present invention for comparison.

[0112] like Figure 2As shown, first, hHGF was well expressed in VM202 as a positive control group. Plasmids 1 to 3 containing CMV series promoters expressed hHGF at relatively high levels, and plasmid 3 containing SV40 polyA expressed hHGF at a lower level than plasmids 1 and 2. Plasmids 4 to 6 containing EF1alpha S series promoters showed relatively significantly low hHGF expression rates.

[0113] [Example 2: Comparison of AAV productivity of candidate plasmids (in vitro)]

[0114] The inventors used the six plasmids of Example 1 to prepare AAV vectors. First, HEK293 cells were inoculated into T225 flasks and three plasmids (pAAV-RC, pAAV-helper, and pAAV-HGF) were co-transfected using PEI. After 72 hours, the cells were collected and AAV was purified, and then the titer of AAV was determined (titration). The results are shown in Figure 2. Figure 3 shown. Figure 3 This is a graph showing the comparative productivity of AAV particles prepared according to the compositions of the AAV vector candidate group of Table 1 of the present invention.

[0115] like Figure 3 As shown, plasmids No. 1 and No. 3 containing CMV series promoters showed the lowest level of AAV productivity, and plasmid No. 2 having bGH polyA showed the best AAV productivity in the group containing CMV series promoters.

[0116] In contrast, plasmids 4 to 6 containing EF1 alpha series promoters showed relatively high levels of AAV productivity compared to plasmids containing CMV series promoters, and plasmid 5 in particular showed an AAV productivity approximately 20 times higher than that of plasmid 1.

[0117] [Example 3: Comparison of hHGF expression rates of candidate plasmids (in vivo)]

[0118] The present inventors produced AAV1 or AAV9 using plasmids No. 1, No. 4, and No. 5 prepared in the previous examples, and plasmid No. 11, which is a plasmid in which the expression gene in plasmid No. 5 is replaced with codon-optimized HGFX7d4, and administered them to mice to compare the expression level of hHGF protein (flHGF) under in vivo conditions.

[0119]

Table 2

[0120]

[0121] The AAV (1×10 10 vg / head) was administered to mice via the intrathecal route, and the lumbar spinal cord (lumbar spinal cord) and dorsal root ganglia (DRG) were collected 7 days later. Protein was extracted from the collected tissue samples using RIPA buffer, and the total protein amount was quantified using the BCA protein analysis kit (ProteinAssay kit) (Thermo Fisher Scientific, Cat#23225). Then, the expression level of hHGF protein was compared using the Human HGF Quantikine ELISA kit (R&D, DHG00). 50uL of spinal cord and dorsal root ganglion (DRG) lysate was placed in each well and mixed evenly to react with the antibody. The human HGF standard in the enzyme-linked immunosorbent assay kit (ELISA kit) was used to draw a standard curve, and the HGF amount of the final sample can be derived using this curve. The results are shown in Figure 4 shown. Figure 4 A graph showing the hHGF expression levels after intrathecal administration to mice after AAV particles were prepared according to the composition of the AAV vector candidate group in Table 2 of the present invention.

[0122] like Figure 4 As shown, contrary to expectations, all AAVs with EF1 alpha series promoters expressed higher amounts of hHGF than AAVs with CMV promoter series. This is contrary to the results in vitro. In particular, the candidate group with HGF-X7-d4 codon optimized in the EF1 alpha promoter expressed significantly higher amounts of hHGF. As a result of quantitative comparison, AAV_#11_codon_optim showed an expression level of about 16 times higher in the spinal cord and about 5 times higher in the dorsal root ganglion (DRG) than AAV_#1.

[0123] Based on the above test results, plasmid No. 11, which has high AAV productivity and high hHGF expression level in vivo, was selected as the final candidate group.

[0124] Although specific parts of the present invention are described in detail above, it should be understood by those skilled in the art that these specific descriptions are merely preferred examples and the scope of the present invention is not limited thereto.

Claims

1. An adeno-associated virus vector comprising a nucleic acid molecule, wherein the nucleic acid molecule comprises: (a) a cytomegalovirus promoter sequence or an elongation factor 1α promoter sequence; and (b) a polynucleic acid sequence encoding hepatocyte growth factor operably linked to the promoter sequence.

2. The adeno-associated viral vector according to claim 1, wherein the hepatocyte growth factor is a hepatocyte growth factor isoform.

3. The adeno-associated viral vector according to claim 2, wherein the hepatocyte growth factor isoform is a full-length hepatocyte growth factor, a deleted variant hepatocyte growth factor, or a combination thereof.

4. The adeno-associated virus vector according to claim 3, wherein The full-length hepatocyte growth factor comprises the amino acid sequence of sequence 1, The deleted variant hepatocyte growth factor comprises the amino acid sequence of sequence 2. 5 . The adeno-associated viral vector according to claim 1 , wherein the polynucleotide sequence encoding the hepatocyte growth factor has at least 95% homology with a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOs. 4 to 9 and SEQ ID NOs.

19. 6 . The adeno-associated viral vector according to claim 1 , wherein the polynucleotide sequence encoding hepatocyte growth factor comprises the nucleotide sequence of SEQ ID NO: 8 or SEQ ID NO:

9.

7. The adeno-associated virus vector according to claim 1, wherein the vector is an adeno-associated virus vector of serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, AAV-DJ / 8, AAV-PHP.Eb, AAV-PHP.S or AAV rh10.

8. The adeno-associated virus vector according to claim 1, wherein the vector is an adeno-associated virus vector of serotype AAV1 or AAV9. 9 . The adeno-associated virus vector according to claim 1 , wherein the cytomegalovirus promoter sequence comprises the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO:

11. 10 . The adeno-associated viral vector according to claim 1 , wherein the elongation factor 1α promoter sequence comprises the nucleotide sequence of sequence 12.

11. The adeno-associated viral vector according to claim 1, wherein the nucleic acid molecule further comprises a polyadenylation sequence.

12. The adeno-associated virus vector of claim 11, wherein the polyadenylation sequence comprises an SV40 polyadenylation sequence, a human growth hormone polyadenylation sequence, a bovine growth hormone polyadenylation sequence, or a combination thereof.

13. The adeno-associated virus vector according to claim 1, wherein the nucleic acid molecule comprises two adeno-associated virus inverted terminal repeat sequences on both sides of the nucleic acid sequence.

14. An isolated host cell comprising the adeno-associated virus vector according to any one of claims 1 to 13.

15. An adeno-associated virus particle comprising the adeno-associated virus vector according to any one of claims 1 to 13.

16. The adeno-associated viral particle according to claim 15, wherein the adeno-associated viral particle is used for intrathecal administration.

17. A pharmaceutical composition for preventing or treating amyotrophic lateral sclerosis or diabetic peripheral neuropathy, comprising the adeno-associated virus particle according to claim 15.

18. The pharmaceutical composition according to claim 17, wherein the diabetic peripheral neuropathy is multiple peripheral neuropathy or focal peripheral neuropathy.

Citation Information

Patent Citations

  • Electronic ignition device

    KR1020220052369A

  • Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor

    WO2003078568A2